(1S,2R)-1-morpholin-4-yl-1-phenylpropan-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2R)-1-morpholin-4-yl-1-phenylpropan-2-amine
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: KPUFYSBGJJQBJI-DGCLKSJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,2R)-1-morpholin-4-yl-1-phenylpropan-2-amine 生成 N-((1RS,2SR)-1-methyl-2-morpholino-2-phenyl-ethyl)-N'-phenyl-thiourea
  参考文献：
  名称：

  The Stereochemistry of Conjugate Additions. A Study of the Addition of Amines to (2-Nitropropenyl)-benzene

  摘要：

  DOI：

  10.1021/ja01580a031
• 作为产物：
  描述：

  苯,(2-硝基-1-丙烯基)-,(E)- 在 lithium aluminium tetrahydride 、 乙醚 、 Petroleum ether 、 苯 作用下， 生成 (1S,2R)-1-morpholin-4-yl-1-phenylpropan-2-amine
  参考文献：
  名称：

  The Stereochemistry of Conjugate Additions. A Study of the Addition of Amines to (2-Nitropropenyl)-benzene

  摘要：

  DOI：

  10.1021/ja01580a031

文献信息

• [EN] HIV INHIBITORS<br/>[FR] INHIBITEURS DU VIH
  申请人：NEW YORK BLOOD CT INC

  公开号：WO2013036676A1

  公开（公告）日：2013-03-14

  Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.

  本文介绍了抑制逆转录病毒的化合物。更具体地，本公开提供了抑制感染人类免疫缺陷病毒或治疗由其引起的感染的小分子化合物。
• Design, Synthesis, and Antiviral Activity of Entry Inhibitors That Target the CD4-Binding Site of HIV-1
  作者：Francesca Curreli、Spreeha Choudhury、Ilya Pyatkin、Victor P. Zagorodnikov、Anna Khulianova Bulay、Andrea Altieri、Young Do Kwon、Peter D. Kwong、Asim K. Debnath

  DOI：10.1021/jm3002247

  日期：2012.5.24

  The CD4 binding site on HIV-1 gp120 has been validated as a drug target to prevent HIV-1 entry to cells. Previously, we identified two small molecule inhibitors consisting of a 2,2,6,6-tetramethylpiperidine ring linked by an oxalamide to a p-halide-substituted phenyl group, which target this site, specifically, a cavity termed "Phe43 cavity". Here we use synthetic chemistry, functional assessment, and structure-based analysis to explore variants of each region of these inhibitors for improved antiviral properties. Alterations of the phenyl group and of the oxalamide linker indicated that these regions were close to optimal in the original lead compounds. Design of a series of compounds, where the tetramethylpiperidine ring was replaced with new scaffolds, led to improved antiviral activity. These new scaffolds provide insight into the surface chemistry at the entrance of the cavity and offer additional opportunities by which to optimize further these potential-next-generation therapeutics and microbicides against HIV-1.